Recent News

• 04.23.2025 - Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
• 04.21.2025 - Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
• 04.03.2025 - Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
• 03.17.2025 - Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
• 03.04.2025 - Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
• 03.04.2025 - Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
• 03.03.2025 - Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
• 03.03.2025 - Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Recent Filings

• 04.21.2025 - EX-99.1 EX-99.1
• 04.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.03.2025 - EX-99.1 EX-99.1
• 04.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.17.2025 - EX-99.1 EX-99.1
• 03.04.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]